Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Novel Compound for Alcoholism Treatment: A Translational Strategy

Trial Profile

A Novel Compound for Alcoholism Treatment: A Translational Strategy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 5190457 (Primary)
  • Indications Alcohol-related disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2019 Results evaluating the biotransformation of PF-51904577 in vitro and from this study's sample in humans were published in the Drug Metabolism and Disposition.
    • 02 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 02 Dec 2014 Planned number of patients changed from 15 to 20 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top